The FDA has approved Awiqli, the first once‑weekly long‑acting basal insulin, for adults with type 2 diabetes, which offers ...

With the increased use of wearable devices for self-monitoring, data sources and inputs could grow exponentially. In both adults and children with diabetes, there is a need to interpret time series ...

For over a century, scientists have chased the dream of insulin pills, but the digestive system kept destroying the drug ...

For more than a century, oral insulin has been considered a "dream" therapy for diabetes, hindered by enzymatic degradation in the digestive tract and the absence of a dedicated intestinal transport ...

Adults with type 1 diabetes had an increase in total daily insulin dose and bolus insulin dose shortly after stopping ...

A University of Virginia Center for Diabetes Technology-developed algorithm – paired with a continuous glucose monitor – can ...

At ATTD 2026, Dexcom (Nasdaq:DXCM) outlined a range of ways in which its continuous glucose monitors (CGMs) benefit people ...

The FDA approved a once-weekly, long-acting basal insulin for adults with type 2 diabetes as an alternative to daily basal ...